Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

Baltic_Roots Dec. 5 at 10:57 PM

$OSCR I dump off all my $JD position with break even and made some good gains on $ASTS +40% in 5 days, now I'm fully in $OSCR with 7650 shares average $17 and have 17k shares in $PDSB

1 · Reply

dvice2 Dec. 5 at 9:59 PM

$PDSB assuming this meeting is happening within the next 2.5 weeks just based on holidays..either way, cheers to everyone still here (either willingly or because you cant sell for a 80% loss 🤣). ”2026 iS oUr YeAr!”

0 · Reply

Mr_Charlie Dec. 5 at 4:41 PM

$PDSB Friday is a selling day. I am not worried.

0 · Reply

dvice2 Dec. 5 at 1:35 PM

$PDSB good podcast posted today. Frank addresses the skepticism around the treatment (that the results are real and able to be replicated) but emphasized that consistent data is being generated across multiple trials with independent studies (ie NCI / MD anderson) and that he believes everything is coming together really nicely as it relates to the clinical and biomarker data. start around 1:09:45 https://youtu.be/Viih778ATqk?si=JMQgzLN1t4Of_r6a

0 · Reply

gth829c Dec. 5 at 12:37 PM

$PDSB this reeks of a buy the hype sell the news run up

1 · Reply

Baltic_Roots Dec. 4 at 11:25 PM

$PDSB If FDA will approve their request it's immediately will indicate that company are moving towards end date rapidly. They will save around 3 years and this will remove fear from investors as they will see that FDA teust a company.... Bullish, in January we will know what to expect, if they approve, I will hold untill the end ... untill butout of company success

0 · Reply

Ontherag Dec. 4 at 9:41 PM

$PDSB Good job, lfg

0 · Reply

Ontherag Dec. 4 at 6:53 PM

$PDSB Wow we actually have significant L2 on the bid

1 · Reply

The__Shane Dec. 4 at 6:00 PM

$PDSB Money and M&A is not Franks problem. The problem is the FDA being scared to do their job. As long as they don't sign off on anything then there is nothing they can get in trouble for. Sad...

0 · Reply

SPYmyQQQ Dec. 4 at 5:13 PM

🎯 Target Hit 🏁 📨 From Nov 20, 2025 💊 $PDSB 💵 Entry: $0.7910 ✅ Ext: $0.9154 💰 P/L: +15.73% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 10:11 AM EST - 22 days ago

PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:30 AM EST - 22 days ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 24 days ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 25 days ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 5 weeks ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 5 weeks ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 2 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 3 months ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 8:30 AM EDT - 3 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 10:08 AM EDT - 4 months ago

PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:00 AM EDT - 4 months ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 4 months ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 5 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 9, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:26 PM EDT - 7 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 12:57 PM EDT - 7 months ago

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 7 months ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 7 months ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 8 months ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 10:35 AM EDT - 9 months ago

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 9 months ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 9 months ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 10 months ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 10 months ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 10 months ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 10 months ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 11:18 AM EST - 1 year ago

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 23, 2024, 10:39 AM EDT - 1 year ago

PDS Biotechnology: Continuing The Holding Pattern

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Aug 2, 2024, 9:12 AM EDT - 1 year ago

PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)

Aug 1, 2024, 7:45 AM EDT - 1 year ago

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Jul 31, 2024, 4:01 PM EDT - 1 year ago

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

May 15, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

Baltic_Roots Dec. 5 at 10:57 PM

$OSCR I dump off all my $JD position with break even and made some good gains on $ASTS +40% in 5 days, now I'm fully in $OSCR with 7650 shares average $17 and have 17k shares in $PDSB

1 · Reply

dvice2 Dec. 5 at 9:59 PM

0 · Reply

Mr_Charlie Dec. 5 at 4:41 PM

$PDSB Friday is a selling day. I am not worried.

0 · Reply

dvice2 Dec. 5 at 1:35 PM

0 · Reply

gth829c Dec. 5 at 12:37 PM

$PDSB this reeks of a buy the hype sell the news run up

1 · Reply

Baltic_Roots Dec. 4 at 11:25 PM

0 · Reply

Ontherag Dec. 4 at 9:41 PM

$PDSB Good job, lfg

0 · Reply

Ontherag Dec. 4 at 6:53 PM

$PDSB Wow we actually have significant L2 on the bid

1 · Reply

The__Shane Dec. 4 at 6:00 PM

$PDSB Money and M&A is not Franks problem. The problem is the FDA being scared to do their job. As long as they don't sign off on anything then there is nothing they can get in trouble for. Sad...

0 · Reply

SPYmyQQQ Dec. 4 at 5:13 PM

🎯 Target Hit 🏁 📨 From Nov 20, 2025 💊 $PDSB 💵 Entry: $0.7910 ✅ Ext: $0.9154 💰 P/L: +15.73% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

Mr_Charlie Dec. 4 at 4:02 PM

$PDSB you don't want be in when news come out. You want to be in before that happens!!

0 · Reply

Mr_Charlie Dec. 4 at 2:03 PM

$PDSB I am positive. FDA will approve quick approval process and a partner will be made public in Jan.

1 · Reply

merlin8121 Dec. 4 at 1:32 PM

$PDSB https://www.merlintrader.com/pdsb/

0 · Reply

Mr_Charlie Dec. 4 at 1:24 PM

$PDSB I think Eddie got it wrong. The trend seems to be reversing and we are going up.

1 · Reply

alphabetsop Dec. 4 at 3:40 AM

$PDSB prefer not to get delisting notice regardless of future price so would like company to get back to $1

0 · Reply

Fishman2001 Dec. 4 at 2:32 AM

$PDSB

0 · Reply

dvice2 Dec. 3 at 11:39 PM

$PDSB major catalyst with this Type C meeting.. unfortunately the cash and dilution overhang doesnt change but it certainly will provide strong validation of the data if the changes are approved. on a side note, dr shepard is coming up on 2 years at the co which is a positive 🤣 hes a heavy hitter and (hopefully) must believe in the data. good luck to us.. crazy this is just about worth less than it was before any meaningful data was announced over 5 yrs ago

1 · Reply

bmess Dec. 3 at 9:47 PM

$MREO $PDSB I’m sad Eddie but best of luck. If this ever hits I still hope to meet you one day 😂

2 · Reply

Mr_Charlie Dec. 3 at 9:02 PM

$PDSB Biggest mistake ever!

1 · Reply

Baltic_Roots Dec. 3 at 8:03 PM

$PDSB this is not a Phase 1 or Phase 3 .... thiiis issss Accumulation Phase 🤣 I hold now 15k shares 💪😁

0 · Reply

EddieH2020 Dec. 3 at 7:58 PM

Sold all $PDSB today for $40K+ loss and rotated into $MREO for data readout. Good luck longs, hope Frank meets his maker one day. 👍

1 · Reply

Ontherag Dec. 3 at 7:08 PM

$PDSB MM probably frothing at the mouth

0 · Reply

Market Cap	37.60M
Revenue (ttm)	0.00
Net Income (ttm)	-37.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.26

Volume	379,600
Avg Vol	818,880
Day's Range	N/A - N/A
Shares Out	48.98M
Stochastic %K	82%
Beta	1.11
Analysts	Strong Sell
Price Target	$7.50